LCTX
Lineage Cell Therapeutics, Inc.·Healthcare
1.48
0.671%(−0.01)
Market ClosedLast Updated: — ET
52W L: $0.4052W H: $2.09
LCTX NEWS
prnewswire.com
23h ago
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
defenseworld.net
Mar 26
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX
Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,829,099 shares of the company's stock, valued at approximately $11,405,000. Lineage Cell Therapeutics comprises approximately 3.7%
businesswire.com
Mar 24
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline with the launch of COR1, a new corneal endothelial cell (CEnC) therapy program, in preclinical development for the treatment of corneal endothelial disease. Corneal endothelial disease is a progressive,.
defenseworld.net
Mar 8
Lineage Cell Therapeutics Q4 Earnings Call Highlights
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early internal validation work in a newly launched islet cell research initiative. Management also reviewed updates across its three most visible programs-OpRegen in geographic atrophy, OPC1 in spinal cord injury, and
seekingalpha.com
Mar 5
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
zacks.com
Mar 5
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
Lineage Cell (LCTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.01 per share a year ago.
